Published in PLoS One on August 14, 2013
Electrospun nanofibers as versatile interfaces for efficient gene delivery. J Biol Eng (2014) 0.78
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov (2004) 6.21
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene (2003) 2.96
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
NF-kappaB and virus infection: who controls whom. EMBO J (2003) 2.08
The human parvovirus. Brief review. Arch Virol (1984) 2.05
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A (1994) 1.91
Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1.82
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55
Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol (2007) 1.54
cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther (1999) 1.39
Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology (2002) 1.38
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst (2011) 1.35
Epidemiology and risk factors in pancreatic cancer. Semin Oncol (1996) 1.31
Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood (1990) 1.29
Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol (1998) 1.27
Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression. J Virol (1988) 1.21
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol (2012) 1.16
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia (2009) 1.15
The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther (2002) 1.12
Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther (2002) 1.12
Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer (2006) 1.11
Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther (2003) 1.07
Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res (1989) 1.06
Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J Virol (1999) 1.06
Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. J Virol (2010) 1.02
New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum Gene Ther (2002) 0.99
H-1 VIRUS VIREMIA IN THE HUMAN. Proc Soc Exp Biol Med (1965) 0.98
p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res (1999) 0.97
Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer (1998) 0.95
NF kappa B upstream regulatory sequences of the HIV-1 LTR are involved in the inhibition of HIV-1 promoter activity by the NS proteins of autonomous parvoviruses H-1 and MVMp. Virology (1993) 0.92
Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther (2000) 0.87
An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. Int J Mol Med (2002) 0.84
Combined suicide gene therapy for pancreatic peritoneal carcinomatosis using BGTC liposomes. Cancer Gene Ther (2004) 0.80
A modified plaque assay and infected cell hybridization assay for wild-type and recombinant LuIII autonomous parvovirus. Biotechniques (1994) 0.79
Pancreatic cancer: who benefits from curative resection? Can J Gastroenterol (2002) 0.78
Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res (2009) 1.36
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia (2009) 1.15
K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci (2007) 1.07
Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am J Pathol (2007) 1.07
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine (2011) 0.99
ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. Biochem J (2007) 0.92
Feasibility, sensitivity, and reliability of laser-induced fluorescence imaging of green fluorescent protein-expressing tumors in vivo. Mol Ther (2003) 0.91
Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int J Oncol (2007) 0.83
Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside. Pancreas (2004) 0.82
Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med (2005) 0.79
Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther (2007) 0.79
Pathological pattern of Mdx mice diaphragm correlates with gradual expression of the short utrophin isoform Up71. Biochim Biophys Acta (2006) 0.78